Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$70.86 -3.1%	$72.75	$32.33 ▼ $117.33	$7.75B	0.15	1.19 million shs	563,090 shs
DCPH Deciphera Pharmaceuticals	$25.59	$25.59	$9.90 ▼ $25.61	$2.21B	0.19	1.29 million shs	600 shs
ORGO Organogenesis	$4.37 +0.2%	$3.44	$2.28 ▼ $6.71	$553.08M	1.7	1.15 million shs	347,407 shs
PCRX Pacira BioSciences	$21.59 -3.1%	$24.61	$11.16 ▼ $27.64	$1.03B	0.48	886,893 shs	601,123 shs
RCKT Rocket Pharmaceuticals	$3.04 -9.0%	$3.65	$2.19 ▼ $26.98	$356.66M	0.67	2.32 million shs	4.00 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	+0.34%	+1.51%	+1.74%	+17.45%	+119.92%
DCPH Deciphera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ORGO Organogenesis	-2.46%	-0.91%	+39.30%	+3.32%	+43.42%
PCRX Pacira BioSciences	-1.37%	-5.91%	-8.61%	-9.57%	+6.19%
RCKT Rocket Pharmaceuticals	+16.78%	+5.70%	+22.79%	-47.24%	-85.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	4.7926 of 5 stars	3.5	3.0	0.0	4.3	2.2	4.2	1.9
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	4.4557 of 5 stars	3.3	3.0	0.0	4.3	1.8	4.2	0.6
PCRX Pacira BioSciences	3.1119 of 5 stars	2.2	1.0	0.0	3.9	2.0	2.5	0.6
RCKT Rocket Pharmaceuticals	4.8495 of 5 stars	4.2	3.0	0.0	4.7	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$138.25	95.10% Upside
DCPH Deciphera Pharmaceuticals	0.00	N/A	N/A	N/A
ORGO Organogenesis	2.67	Moderate Buy	$6.50	48.74% Upside
PCRX Pacira BioSciences	2.33	Hold	$26.44	22.48% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	511.84% Upside

Current Analyst Ratings Breakdown

Latest PCRX, ORGO, DCPH, RCKT, and CORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ORGO Organogenesis	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/15/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$675.04M	11.13	$1.20 per share	58.86	$6.49 per share	10.92
DCPH Deciphera Pharmaceuticals	$174.91M	12.65	N/A	N/A	$4.38 per share	5.84
ORGO Organogenesis	$482.04M	1.15	$0.21 per share	20.89	$2.09 per share	2.09
PCRX Pacira BioSciences	$700.97M	1.43	$4.18 per share	5.16	$16.86 per share	1.28
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$141.21M	$1.16	63.02	38.30	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
DCPH Deciphera Pharmaceuticals	-$194.94M	-$2.21	N/A	N/A	N/A	-108.86%	-52.42%	-40.05%	N/A
ORGO Organogenesis	$860K	-$0.17	0.00	N/A	N/A	-3.46%	-4.00%	-2.26%	8/6/2025 (Estimated)
PCRX Pacira BioSciences	-$99.56M	-$2.28	9.82	8.40	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	0.00	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest PCRX, ORGO, DCPH, RCKT, and CORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
7/29/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	N/A	N/A	N/A	$183.11 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	ORGO Organogenesis	$0.04	-$0.13	-$0.17	-$0.17	$90.77 million	$86.69 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
DCPH Deciphera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	3.07	2.96
DCPH Deciphera Pharmaceuticals	N/A	4.19	3.94
ORGO Organogenesis	N/A	4.12	3.67
PCRX Pacira BioSciences	0.48	2.41	1.99
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
DCPH Deciphera Pharmaceuticals	70.96%
ORGO Organogenesis	49.57%
PCRX Pacira BioSciences	99.73%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.80%
DCPH Deciphera Pharmaceuticals	4.67%
ORGO Organogenesis	33.00%
PCRX Pacira BioSciences	6.40%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
DCPH Deciphera Pharmaceuticals	300	86.48 million	82.44 million	Optionable
ORGO Organogenesis	950	126.85 million	84.99 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

PCRX, ORGO, DCPH, RCKT, and CORT Headlines

Recent News About These Companies

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

July 18 at 12:31 PM | zacks.com

Deadline Alert: Rocket Pharmaceuticals, Inc. ...

July 18 at 12:08 PM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. ...

July 18 at 9:31 AM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors - Contact Levi & Korsinsky

July 18 at 8:45 AM | prnewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 17 at 6:05 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

July 17 at 4:15 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 17 at 4:00 PM | globenewswire.com

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman

July 17 at 3:07 PM | globenewswire.com

Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals stock surges after FDA grants key designation

July 17 at 1:42 PM | investing.com

Rocket Pharmaceuticals Shares Jump After FDA Grants Accelerated Review Status to Gene Therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 17 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 17 at 10:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKT

July 17 at 9:00 AM | prnewswire.com

NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors of August 11, 2025 Deadline

July 17 at 8:36 AM | globenewswire.com

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

July 17 at 7:00 AM | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Brokerages

July 17 at 2:46 AM | marketbeat.com

B2B Rocket joins publicly traded tech powerhouse in move to scale smarter and faster

July 16 at 5:38 PM | manilatimes.netM

Virgin Islands Students Complete Elite NASA-Style Training at U.S. Space & Rocket Center

July 16 at 5:38 PM | viconsortium.comV

Army Unit in Hawaii Receives Long-range Rocket Artillery for Pacific Operations

July 16 at 5:38 PM | news.usni.orgN

Rocket Pharmaceuticals, Inc. (RCKT) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights

July 16 at 4:44 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX, ORGO, DCPH, RCKT, and CORT Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$70.86 -2.24 (-3.06%)

Closing price 04:00 PM Eastern

Extended Trading

$71.66 +0.80 (+1.12%)

As of 06:22 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Organogenesis NASDAQ:ORGO

$4.37 +0.01 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.33 -0.04 (-0.89%)

As of 07:38 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Pacira BioSciences NASDAQ:PCRX

$21.59 -0.70 (-3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$21.58 0.00 (-0.02%)

As of 07:19 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.04 -0.30 (-8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.04 (+1.32%)

As of 07:53 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time